Oppenheimer Maintains Outperform on Boston Scientific, Lowers Price Target to $65

Benzinga Newsdesk www.benzinga.com Negative 94.8%

Neg 94.8% Neu 0% Pos 0%

Oppenheimer analyst Suraj Kalia maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $85 to $65.